US 12,433,957 B2
Compositions and methods for delivery of RNA
Amit Khandhar, Issaquah, WA (US); Steven Reed, Bellevue, WA (US); Malcolm Duthie, Sammamish, WA (US); Jesse Erasmus, Port Orchard, WA (US); Darrick Carter, Seattle, WA (US); and Bryan J. Berube, Issaquah, WA (US)
Assigned to HDT Bio Corp., Seattle, WA (US)
Filed by HDT Bio Corp., Seattle, WA (US)
Filed on Sep. 23, 2024, as Appl. No. 18/893,280.
Application 18/893,280 is a continuation of application No. 18/390,700, filed on Dec. 20, 2023, granted, now 12,133,894.
Application 18/390,700 is a continuation of application No. 18/357,280, filed on Jul. 24, 2023, granted, now 11,896,677, issued on Feb. 13, 2024.
Application 18/357,280 is a continuation of application No. 17/839,574, filed on Jun. 14, 2022, granted, now 11,752,218, issued on Sep. 12, 2023.
Application 17/839,574 is a continuation of application No. 17/702,730, filed on Mar. 23, 2022, granted, now 11,433,142, issued on Sep. 6, 2022.
Application 17/702,730 is a continuation of application No. 17/523,457, filed on Nov. 10, 2021, granted, now 11,318,213, issued on May 3, 2022.
Application 17/523,457 is a continuation of application No. PCT/US2021/019103, filed on Feb. 22, 2021.
Claims priority of provisional application 63/054,754, filed on Jul. 21, 2020.
Claims priority of provisional application 62/993,307, filed on Mar. 23, 2020.
Prior Publication US 2025/0032639 A1, Jan. 30, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/713 (2006.01); A61K 39/215 (2006.01); A61K 39/39 (2006.01); A61K 47/02 (2006.01); A61K 47/44 (2017.01); A61K 49/18 (2006.01); A61P 31/14 (2006.01); C07K 14/165 (2006.01); C12N 15/86 (2006.01); C12N 15/88 (2006.01); A61K 39/00 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/54 (2017.01); B82Y 5/00 (2011.01); B82Y 25/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01)
CPC A61K 47/6907 (2017.08) [A61K 9/1075 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); A61K 9/5123 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 39/215 (2013.01); A61K 39/39 (2013.01); A61K 47/02 (2013.01); A61K 47/44 (2013.01); A61K 47/6911 (2017.08); A61K 47/6923 (2017.08); A61K 49/183 (2013.01); A61K 49/1833 (2013.01); A61P 31/14 (2018.01); C07K 14/165 (2013.01); C12N 15/86 (2013.01); C12N 15/88 (2013.01); A61K 2039/55555 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/547 (2017.08); B82Y 5/00 (2013.01); B82Y 25/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C12N 2770/36143 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A composition, wherein the composition comprises:
lipid nanoparticles, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:
a surface comprising cationic lipids; and
a hydrophobic core that comprises liquid oil, wherein lipids present in the hydrophobic core are in liquid phase at 25 degrees Celsius,
at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for an RNA-dependent polymerase and a non-coding RNA.